As early as 2013, transgenic mice studies demonstrated that FGF21 KO mice suffered maladaptive cardiac hypertrophy and dilatation in response to isoproterenol challenge and that the maladaptive responses were reversed by treatment with exogenous FGF21 [41]. The gene discussed is FGF21; the disease is cardiac hypertrophy.